Meeder Asset Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Meeder Asset Management’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.14K	Sell	84 -93	-53%	-$3.46K	﹤0.01%	895
2026 Q1	$6.43K	Buy	177 +128	+261%	+$5.72K	﹤0.01%	785
2025 Q4	$2.28K	Sell	49 -69	-58%	-$3.07K	﹤0.01%	861
2025 Q3	$4.92K	Buy	118 +20	+20%	+$639	﹤0.01%	678
2025 Q2	$2.82K	Buy	98 +34	+53%	+$1.05K	﹤0.01%	785
2025 Q1	$2.15K	Sell	64 -17	-21%	-$635	﹤0.01%	863
2024 Q4	$4.14K	Buy	81 +5	+7%	+$280	﹤0.01%	853
2024 Q3	$3.88K	Buy	+76	New	+$3.92K	﹤0.01%	782
2021 Q4	–	Sell	-1,988	Closed	-$42K	–	1420
2021 Q3	$42K	Buy	+1,988	New	+$41.6K	﹤0.01%	1143

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jupiter Topco New York $245B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Meeder Asset Management's CRNX Position: Q2 2026 in Review

Meeder Asset Management reduced its Crinetics Pharmaceuticals (CRNX) stake by 53% in Q2 2026, selling an estimated $3.46K and leaving 84 shares worth $3.14K. The position accounts for ﹤0.01% of the portfolio, ranked #895.

Meeder Asset Management first reported a position in CRNX in Q3 2021 and has held it in 9 quarters since. The position peaked at $42K in Q3 2021. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

Meeder Asset Management held 84 shares of Crinetics Pharmaceuticals worth $3.14K as of Q2 2026.
Meeder Asset Management sold 93 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $3.46K.
Crinetics Pharmaceuticals made up ﹤0.01% of Meeder Asset Management's portfolio in Q2 2026, its #895 holding.
Meeder Asset Management first reported a position in Crinetics Pharmaceuticals in Q3 2021 and has held it in 9 quarters since.
Meeder Asset Management's Crinetics Pharmaceuticals position peaked at $42K in Q3 2021.
267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Meeder Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.